Conditions: Crohn's Disease
Keywords: Ileal Crohn's Disease Ileo-colonic Crohn's Disease Colonic Chron's Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 130
Healthy volunteers: no

Brief summary:
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is being given.

Detailed description:

Arms:
arm 1: Participants received placebo intravenously at baseline and week 4. arm 2: Participants received 210 mg brodalumab intravenously at baseline and week 4. arm 3: Participants received 350 mg brodalumab intravenously at baseline and week 4. arm 4: Participants received 700 mg brodalumab intravenously at baseline and week 4.

Interventions: intervention 1: Brodalumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered as as an intravenous (IV) infusion over at least 30 minutes. intervention 2: Administered as as an intravenous (IV) infusion over at least 30 minutes.

Protocol document: